Evidence map›Paper›PMID 26976043›Full record

ArticleMolecular psychiatry2017

Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.

A Lacour, A Espinosa, E Louwersheimer, S Heilmann, I Hernández, S Wolfsgruber, V Fernández, H Wagner, M Rosende-Roca, A Mauleón and 29 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Correlations between the NMR Lipoprotein Profile,International journal of molecular sciences · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 14 institutions in 3 countries.

A LacourGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
A EspinosaMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
E LouwersheimerDepartment of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
S HeilmannInstitute of Human Genetics, University of Bonn, Bonn, Germany.
I HernándezMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
S WolfsgruberGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
V FernándezMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
H WagnerDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany.
M Rosende-RocaMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
A MauleónMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
S Moreno-GrauMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
L VargasMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
Y A L PijnenburgDepartment of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
T KoeneDepartment of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
O Rodríguez-GómezMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
G OrtegaMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
S RuizMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
H HolstegeAlzheimer Center and Department of Clinical Genetics, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
O Sotolongo-GrauMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
J KornhuberDepartment of Psychiatry and Psychotherapy, University Clinic Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
O PetersDepartment of Psychiatry, Charité University Medicine, Berlin, Germany.
L FrölichDepartment of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
M HüllCenter for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany.
E RütherDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
J WiltfangDepartment of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
M SchererDepartment of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
S Riedel-HellerInstitute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany.
M AlegretMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
M M NöthenInstitute of Human Genetics, University of Bonn, Bonn, Germany.
P ScheltensDepartment of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
M WagnerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
L TárragaMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
F JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
M BoadaMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
W MaierGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
W M van der FlierDepartment of Neurology and Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
T BeckerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
A RamirezInstitute of Human Genetics, University of Bonn, Bonn, Germany.
A RuizMemory Clinic and Research Center of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain.
Fundació ACE · ESAmsterdam Neuroscience · NLUniversity of Bonn · DEGerman Center for Neurodegenerative Diseases · DEUniversity of Göttingen · DECharité - Universitätsmedizin Berlin · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHeidelberg University · DEInstitut für Medizinische Biometrie, Informatik und Epidemiologie · DELeipzig University · DELife & Brain (Germany) · DEUniversität Hamburg · DEUniversity of Cologne · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few data are available concerning the role of risk markers for Alzheimer's disease (AD) in progression to AD dementia among subjects with mild cognitive impairment (MCI). We therefore investigated the role of well-known AD-associated single-nucleotide polymorphism (SNP) in the progression from MCI to AD dementia. Four independent MCI data sets were included in the analysis: (a) the German study on Aging, Cognition and Dementia in primary care patients (n=853); (b) the German Dementia Competence Network (n=812); (c) the Fundació ACE from Barcelona, Spain (n=1245); and (d) the MCI data set of the Amsterdam Dementia Cohort (n=306). The effects of single markers and combined polygenic scores were measured using Cox proportional hazards models and meta-analyses. The clusterin (CLU) locus was an independent genetic risk factor for MCI to AD progression (CLU rs9331888: hazard ratio (HR)=1.187 (1.054-1.32); P=0.0035). A polygenic score (PGS1) comprising nine established genome-wide AD risk loci predicted a small effect on the risk of MCI to AD progression in APOE-ɛ4 (apolipoprotein E-ɛ4) carriers (HR=1.746 (1.029-2.965); P=0.038). The novel AD loci reported by the International Genomics of Alzheimer's Project were not implicated in MCI to AD dementia progression. SNP-based polygenic risk scores comprising currently available AD genetic markers did not predict MCI to AD progression. We conclude that SNPs in CLU are potential markers for MCI to AD progression.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseApolipoprotein E4BiomarkersClusterinCognitive DysfunctionDementiaDisease ProgressionFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMiddle AgedApolipoprotein E4BiomarkersCLU protein, humanClusterin

Identifiers

PMID26976043
PMCPMC5414086
OpenAlexW2301413049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.